This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Amir, S. Articles by Mabjeesh, N. J. Search for Related Content PubMed PubMed Citation Articles by Amir, S. Articles by Mabjeesh, N. J.

MSF-A Interacts with Hypoxia-Inducible Factor-1 and Augments Hypoxia-Inducible Factor Transcriptional Activation to Affect Tumorigenicity and Angiogenesis

¹ Prostate Cancer Research Laboratory, Department of Urology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel and ² Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia

Requests for reprints: Nicola J. Mabjeesh, Prostate Cancer Research Laboratory, Department of Urology, Tel Aviv Sourasky Medical Center, 6 Weizmann Street, 64239 Tel Aviv, Israel. Phone: 972-52-4262863; Fax: 972-3-6973183/6973798; E-mail: nicolam{at}tasmc.health.gov.il.

Hypoxia-inducible factor-1 (HIF-1) is a key transcription factor in the signaling pathway that controls the hypoxic responses of cancer cells. Activation of the HIF system has been observed in carcinogenesis and numerous cancers. We found an interaction between a member of the mammalian septin gene family (MSF-A) and the HIF system. MSF-A is a nuclear protein that interacts with HIF-1 protein to prevent its ubiquitination and degradation, thus activating the HIF transcriptome. Cells overexpressing MSF-A protein exhibit increased HIF transcriptional activity and higher proliferation rates in vitro and in vivo. Xenograft-derived human tumors from these cells were larger and more vascular. These findings link a function of a septin protein with angiogenesis through activation of the HIF pathway. (Cancer Res 2006; 66(2): 856-66)

This article has been cited by other articles:

				S. Amir, R. Wang, J. W. Simons, and N. J. Mabjeesh SEPT9_v1 Up-regulates Hypoxia-inducible Factor 1 by Preventing Its RACK1-mediated Degradation J. Biol. Chem., April 24, 2009; 284(17): 11142 - 11151. [Abstract] [Full Text] [PDF]

				K. L. Bennett, M. Karpenko, M.-t. Lin, R. Claus, K. Arab, G. Dyckhoff, P. Plinkert, E. Herpel, D. Smiraglia, and C. Plass Frequently Methylated Tumor Suppressor Genes in Head and Neck Squamous Cell Carcinoma Cancer Res., June 15, 2008; 68(12): 4494 - 4499. [Abstract] [Full Text] [PDF]

				M. E. Gonzalez, E. A. Peterson, L. M. Privette, J. L. Loffreda-Wren, L. M. Kalikin, and E. M. Petty High SEPT9_v1 Expression in Human Breast Cancer Cells Is Associated with Oncogenic Phenotypes Cancer Res., September 15, 2007; 67(18): 8554 - 8564. [Abstract] [Full Text] [PDF]

				S. S. McDade, P. A. Hall, and S.E. H. Russell Translational control of SEPT9 isoforms is perturbed in disease Hum. Mol. Genet., April 1, 2007; 16(7): 742 - 752. [Abstract] [Full Text] [PDF]

				M. Ben-Shoshan, S. Amir, D. T. Dang, L. H. Dang, Y. Weisman, and N. J. Mabjeesh 1{alpha},25-dihydroxyvitamin D3 (Calcitriol) inhibits hypoxia-inducible factor-1/vascular endothelial growth factor pathway in human cancer cells Mol. Cancer Ther., April 1, 2007; 6(4): 1433 - 1439. [Abstract] [Full Text] [PDF]